|1.||Kannappan, Ramaswamy: 1 article (11/2011)|
|2.||Aggarwal, Bharat B: 1 article (11/2011)|
|3.||Das, Joydip: 1 article (11/2011)|
|4.||Rahman, Ghazi M: 1 article (11/2011)|
|5.||Francis, Sajin K: 1 article (11/2011)|
|6.||Raveendran, Reshma: 1 article (11/2011)|
|7.||Gupta, Subash C: 1 article (11/2011)|
|8.||Kim, Jihye: 1 article (11/2011)|
|9.||Nair, Mangalam S: 1 article (11/2011)|
11/01/2011 - "Overall, our results demonstrate that bharangin specifically inhibits the NF-κB activation pathway by modifying p65 and inhibiting IκBα kinase activation and potentiates apoptosis in tumor cells."
11/01/2011 - "We found that bharangin suppresses nuclear factor (NF)-κB activation induced by pro-inflammatory cytokine, tumor promoter, cigarette smoke, and endotoxin. "
11/01/2011 - "Bharangin, a diterpenoid quinonemethide, abolishes constitutive and inducible nuclear factor-κB (NF-κB) activation by modifying p65 on cysteine 38 residue and reducing inhibitor of nuclear factor-κB α kinase activation, leading to suppression of NF-κB-regulated gene expression and sensitization of tumor cells to chemotherapeutic agents."